Shots:
- The ANVISA has approved Eydenzelt, a biosimilar version of Eylea (aflibercept)
- Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor
- Eydenzelt is indicated for adults with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (CRVO/BRVO), diabetic macular edema (DME), and myopic choroidal neovascularization (CNV)
Ref: Gov.br | Image: Celltrion | Press Release
Related News: Celltrion Plans to File for Approval of Herzuma SC (Biosimilar, Herceptin) in Europe and Korea
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
